Chemical Property of Pepcid
Chemical Property:
- Appearance/Colour:white powder
- Melting Point:163-164 °C
- Refractive Index:1.7400 (estimate)
- Boiling Point:662.383 °C at 760 mmHg
- PKA:pKa 6.76(H2O t=23.0) (Uncertain)
- Flash Point:354.397 °C
- PSA：235.25000
- Density:1.838 g/cm3
- LogP:3.11400
- Storage Temp.:Hygroscopic, -20°C Freezer, Under Inert Atmosphere
- Solubility.:Very slightly soluble in water, freely soluble in glacial acetic acid, very slightly soluble in anhydrous ethanol, practically insoluble in ethyl acetate. It dissolves in dilute mineral acids
- Water Solubility.:1.1 mg/mL
- XLogP3:-0.6
- Hydrogen Bond Donor Count:4
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:7
- Exact Mass:337.04493627
- Heavy Atom Count:20
- Complexity:469
- Purity/Quality:
-
98.5%-101.0%, *data from raw suppliers
Famotidine
*data from reagent suppliers
Safty Information:
- Pictogram(s):
T
- Hazard Codes:T
- Statements:
20/21/22-45-61
- Safety Statements:
22-24/25-53-45-36/37/39
- MSDS Files:
-
SDS file from LookChem
Useful:
- Chemical Classes:Other Uses -> Pharmaceuticals
- Drug Classes:Antiulcer Agents
- Canonical SMILES:C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N
- Isomeric SMILES:C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
- Recent ClinicalTrials:A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
- Recent EU Clinical Trials:Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative
- Recent NIPH Clinical Trials:Establishment of the algorithm for reccurent infant wheezing under 2 years of age
-
Description
Famotidine (Chemical formula: C8H15N7O2S3; Brand Name: PEPCID) belongs to a histamine H2-receptor antagonist. It appears as a white to pale yellow crystalline compound. Inside the body, its primary activity is inhibiting the gastric secretion process, further reducing the acid concentration and volume of gastric secretion in the stomach. Based on this property, it is used for the treatment and prevention of ulcers occurring in the stomach and intestines. It can also treat diseases such as Zollinger-Ellison syndrome in which the stomach accumulates excess amount of acids. Moreover, it is also applied during the treatment of gastroesophageal reflux disease (GERD) and pathological hypersecretory conditions. Famotidine is a competitive histamine H2-receptor antagonist, and the main pharmacodynamic
effect of famotidine is to cause the inhibition of gastric secretion. Famotidine on
decomposition releases toxic products such as carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), and sulphur oxides (SO2, SO3). Famotidine is a medication that is available both
in prescription and over-the-counter forms. It is used to treat conditions related to the
oesophagus, stomach, and intestines. Some specific famotidine is used for the treatment of
duodenal ulcers, gastric ulcers (stomach ulcers), gastroesophageal reflux disease (GERD),
and pathological hypersecretory conditions that occur when stomach acid is secreted/
produced in very large quantities, an abnormal health condition called ‘Zollinger-Ellison
syndrome’.
-
Uses
Contact dermatitis from famotidine, a H2 -receptor
agonist, was described in a nurse. In industry, three
cases were reported due to intermediates of synthesis, 2-
diamino-ethylene-amino-thiazolyl-methylenethiourea-dichloride
and 4-chloromethyl-2-guanidinothiazolenitrochloride. Histamine H2-receptor antagonist. Antiulcerative. For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Use as an H2-antagonist. An anti-ulcer agent
-
Therapeutic Function
Antiulcer
-
Clinical Use
Famotidine is a histamine H2-antagonist more potent than cimetidine and
ranitidine. Administered once or twice daily, it is useful in the treatment of
gastric, duodenal and anastomotic ulcers, upper gastrointestinal tract hemorrhage,
reflux esophagitis and Zollinger-Ellison syndrome. Like ranitidine, it is lacking in
antiandrogenic effects.
-
Drug interactions
Potentially hazardous interactions with other drugs
Antifungals: absorption of itraconazole and
ketoconazole reduced; concentration of posaconazole
possibly reduced - avoid with suspension.
Antivirals: concentration of atazanavir reduced
- adjust doses of both drugs; concentration of
raltegravir possibly increased - avoid; avoid for 12
hours before and 4 hours after rilpivirine.
Ciclosporin: possibly increased ciclosporin levels.
Cytotoxics: possibly reduced dasatinib concentration
- avoid if possible; avoid with erlotinib; possibly
reduced absorption of pazopanib - give at least 2
hours before or 10 hours after famotidine; possibly
reduced absorption of lapatinib.
Ulipristal: contraceptive effect possibly reduced -
avoid with high dose ulipristal.
